In the context of feline fibrosarcoma, adjuvant immunotherapy with local injection of recombinant human IL-2 extended survival times [63] and local canarypox-vectored recombinant IL-2 immunotherapy significantly reduced recurrence rates in cat fibrosarcomas [64, 65]. Here, IL2 is linked to fibrosarcoma.